SurVaxM with standard therapy in newly diagnosed glioblastoma: Phase II trial update.

2016Background: SVN53-67/M57-KLH (SurVaxM) is a novel cancer vaccine designed to stimulate an immune response targeting the tumor-specific antigen survivin. A multi-center, single-arm phase 2 clini...